These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

702 related items for PubMed ID: 22272729

  • 1. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST.
    Am J Cardiovasc Drugs; 2012 Feb 01; 12(1):57-72. PubMed ID: 22272729
    [Abstract] [Full Text] [Related]

  • 2. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.
    Health Technol Assess; 2009 Oct 01; 13 Suppl 3():43-8. PubMed ID: 19846028
    [Abstract] [Full Text] [Related]

  • 3. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.
    J Med Econ; 2011 Oct 01; 14(6):824-34. PubMed ID: 22023098
    [Abstract] [Full Text] [Related]

  • 4. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators.
    N Engl J Med; 2008 Jun 26; 358(26):2776-86. PubMed ID: 18579812
    [Abstract] [Full Text] [Related]

  • 5. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
    Nieto JA, Espada NG, Merino RG, González TC.
    Thromb Res; 2012 Aug 26; 130(2):183-91. PubMed ID: 22425218
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM.
    Am J Manag Care; 2011 Feb 26; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
    Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H.
    Thromb Haemost; 2010 Oct 26; 104(4):760-70. PubMed ID: 20806107
    [Abstract] [Full Text] [Related]

  • 8. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group.
    N Engl J Med; 2008 Jun 26; 358(26):2765-75. PubMed ID: 18579811
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
    McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J.
    J Med Econ; 2012 Jun 26; 15(5):817-28. PubMed ID: 22494267
    [Abstract] [Full Text] [Related]

  • 10. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
    Duggan ST, Scott LJ, Plosker GL.
    Drugs; 2009 Jun 26; 69(13):1829-51. PubMed ID: 19719335
    [Abstract] [Full Text] [Related]

  • 11. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P.
    Thromb Res; 2007 Jun 26; 120(5):685-93. PubMed ID: 17292948
    [Abstract] [Full Text] [Related]

  • 12. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
    Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK.
    Thromb Haemost; 2011 Mar 26; 105(3):444-53. PubMed ID: 21136019
    [Abstract] [Full Text] [Related]

  • 13. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators.
    Circulation; 2006 Nov 28; 114(22):2374-81. PubMed ID: 17116766
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M.
    Thromb Haemost; 2013 Nov 28; 110(5):987-94. PubMed ID: 23965805
    [Abstract] [Full Text] [Related]

  • 15. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
    Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.
    Pharmacoeconomics; 2012 Feb 01; 30(2):87-101. PubMed ID: 22187932
    [Abstract] [Full Text] [Related]

  • 16. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV, Quinlan DJ, Dahl OE, Schulman S.
    Circ Cardiovasc Qual Outcomes; 2010 Nov 01; 3(6):652-60. PubMed ID: 20923996
    [Abstract] [Full Text] [Related]

  • 17. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
    Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.
    J Med Econ; 2011 Nov 01; 14(3):324-34. PubMed ID: 21506632
    [Abstract] [Full Text] [Related]

  • 18. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
    Lassen MR, Gent M, Kakkar AK, Eriksson BI, Homering M, Berkowitz SD, Turpie AG.
    J Bone Joint Surg Br; 2012 Nov 01; 94(11):1573-8. PubMed ID: 23109641
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.
    Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I.
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct 01; 11(5):601-15. PubMed ID: 21958104
    [Abstract] [Full Text] [Related]

  • 20. Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.
    Verhamme P, Gunn S, Sonesson E, Peerlinck K, Vanassche T, Vandenbriele C, Ageno W, Glazer S, Prins M, Buller H, Tangelder M.
    Thromb Haemost; 2013 Jun 01; 109(6):1091-8. PubMed ID: 23615791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.